39. Cell Mediated Immunity I

Question 1

A patient with cancer should be treated with a medication that blocks which of the following T cell stimulators?

A.  CD28
B. ICOS 
C. CD86
D. CD152
E. CD80 

RFA

Answer 1

Ans. D. CD152= CTLA-4 mediates suppressive function of regulatory T Cells, communicates with B7-2 (CD86)

A. CD28- activates naive T cells , communicates with B7-1 (CD80)

B. ICOS- activates follicular helper T cells, communicates with ICOS-L (CD275)

C. CD86- is B7-2 it is on the APC that communicates with CTLA-4( CD 152), but since it said that he issue was with the T cell this is wrong

E. CD80- is B7-1 which is on the APC and communicates with the excitatory CD28

Question 2

A 28 year old man was burned in house fire. Due to the severity of the burns he has undergone a skin graft for his torso. Two days after the procedure his body starts to reject the graft. What should the patient be treated with?

A. CD 40 Antibodies 
B. CD128 blocker 
C. PD-1 stimulator 
D. CTLA-4 inhibitor 
E. ICOS Stimulator 

RFA

Answer 2

Ans. B CD128 blocker are used for rheumatoid arthrits and graft rejections.

A. CD 40 Antibodies are tested for graft rejection

C PD-1 Stimulator- might work since it inhibits but isn’t stated anywhere in the lecture so no

D. CTLA-4 inhibitors are used for cancer patients

E. ICOS Stimulator- would increase immune response so that would be the opposite of the effect you want.

Question 3

Which of the following is the first cytokine to be produced by CD4+ T cells 1-2 hours after activation?

A. CD40L
B. CD25
C. CD69
D. IL-2
E. IL-17

SZ

Answer 3

Ans. D IL-2

IL-2 is the first cytokine to be produced after activation. CD40L is the last one to be produced 5 hours after activation.

Question 4

SCIDs (Severe Combined Immunodeficiency) is due to a defect or mutation of which of the following?

A. IL-2
B. CD28
C. CD40L
D. ICOS
E. Fas/Fas-L

SZ

Answer 4

Ans. A IL-2

SCIDs is due to the IL-2 chain or IL-2 receptor mutation or defect. Therefore there is no activation and no cell immunity occurs.

Fas/Fas-L mutation causes Autoimmune Lymphoproliferative Syndrome (ALPS). There is non cancer proliferation but no apoptosis due to the t.